Table 2.

Costs inputs

Drug/input	Cost (€)	Unit
Drug acquisition costs a
SEC 150 mg	584.43	Per dose
SEC 300 mg	1168.86	Per dose
CER P 200 mg	483.07	Per prefilled syringe
ETN 50 mg	260.04	Per prefilled syringe
ADA 40 mg	527.41	Per prefilled syringe
INF 100 mg	436.06	Per vial
GOL 50 mg	1086.93	Per prefilled syringe
UST 45/90 mg	3124.96	Per prefilled syringe
APR 10–30 mg	418.52	Per 14 day pack
APR 30 mg	14.93	Per tablet
ETN biosimilar 50 mg	182.02	Per prefilled syringe
ADA biosimilar 40 mg	369.19	Per prefilled syringe
MTX 7.5 mg	0.51	Per dose
Disease-related costs
Intercept	297.89	Per 3 months
Cost per HAQ change	131.61	Per 1-unit change per 3-months
Health states
Uncontrolled psoriasis (PASI < 75)	253.14	Per 3 months
Controlled psoriasis (PASI ≥ 75)	20.46	Per 3 months

ADA, adalimumab; APR, apremilast; CER P, certolizumab pegol; ETN, etanercept; GOL, golimumab; HAQ, Health Assessment Questionnaire; INF, infliximab; LEF, leflunomide; MTX, methotrexate; PASI, Psoriasis Area Severity Index; SEC, secukinumab; SUL, sulfasalazine; UST, ustekinumab

Source: Costs from the York model (Rodgers et al., [28]) who extracted costs from the following sources. Cost for a 1-point change in HAQ obtained from Kobelt et al. [49]. Cost for uncontrolled psoriasis obtained from Department of Health [50]. Cost for controlled psoriasis obtained from Hartman et al. [51]

^aFinnish medicinal products and prices database [accessed on-line 2.1.2018]. All prices exclude value added tax. Retail price for SC products, and wholesale price for IV products is applied according to local guidelines. Infliximab price is weighed with market share. A cost of €382 (2016 value) is added for each IV administration [48] Biosimilar pricing for etanercept and adalimumab assumed to be 30% less than brand; they were not available in the market at the time of analyses, and thus only used for sensitivity analysis